Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Smoking Cessation market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Smoking Cessation market size from 2017 to 2030. The Report also covers current Smoking Cessation treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.
Geography Covered
Smoking Cessation Understanding and Treatment Algorithm
Smoking Cessation Overview
Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.
The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.
Smoking Cessation Symptoms
Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like “riding a roller coaster”—there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2–4 weeks after stopping.
Continued in the report
Smoking Cessation Treatment
The treatment of smoking includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.
Varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Nortriptyline and clonidine are also used in smoking cessation as off-label medicines.
In the United States, NRT is available over the counter or by prescription as patches, gum, and lozenges, and by prescription only as a nasal spray and oral inhaler. NRT provides nicotine to reduce withdrawal symptoms, including irritability, anxiety, difficulty concentrating, dysphoria, hunger, weight gain, and sleep disturbances, which occur when a smoker stops smoking.
Non-pharmacological treatments for tobacco dependence include behavioral skills training using cognitive behavioral therapy techniques, motivational interviewing, and incentives to motivate and reinforce behavior change.
Smoking Cessation Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Key Findings
The epidemiology segment also provides the Smoking Cessation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Smoking Cessation Drug Chapters
The drug chapter segment of the Smoking Cessation report encloses the detailed analysis of Smoking Cessation current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the Smoking Cessation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.
Smoking Cessation Marketed Drugs
Varenicline (Chantix/Champix): Pfizer
Varenicline is a medication used for smoking cessation aids. It works by blocking the pleasant effects of nicotine (from smoking) on the brain. It is used together with behavior modification and counseling support to help stop smoking. In May 2006, the US FDA approved varenicline (Chantix, Champix) for use in smoking cessation; it was the first oral non?nicotine treatment licensed by the FDA. It was also approved in the EU and Japan for smoking cessation. Patients should be treated with Chantix for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks of treatment with Chantix is recommended to increase the likelihood of long-term abstinence further.
Varenicline binds with high affinity and selectivity at ?4?2 neuronal nicotinic acetylcholine receptors. The efficacy of Chantix in smoking cessation is believed to be the result of varenicline’s activity at the ?4?2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.
Products detail in the report…
Bupropion (Zyban): GlaxoSmithKline
Bupropion is a selective inhibitor of the neuronal reuptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin). It is indicated as an aid to smoking cessation treatment. The exact mechanism by which Zyban enhances the ability of patients to abstain from smoking is not known but is presumed to be related to noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase. The FDA approved it in 1997. It is also approved in the EU for the treatment of smoking cessation.
Products detail in the report…
Smoking Cessation Emerging Drugs
AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, in clinical development for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and smoking cessation. The drug consists of dextromethorphan (DM) and bupropion and utilizes Axsome’s metabolic inhibition technology. The DM component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and an inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor. Both components are nicotinic acetylcholine receptor antagonists and have demonstrated anti-inflammatory properties. The company plans to meet with the FDA in the second half of 2020 to discuss the continued clinical development of AXS-05 as an aid to smoking cessation treatment.
Products detail in the report…
Nadolol (INV102): Chronic Airway Therapeutics
Nadolol (INV102) is a beta-adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium to treat chronic respiratory diseases. Used acutely, Nadolol blocks both ?1 and ?2 receptors, causing a decrease in heart rate and blood pressure via ?1 receptors, which are located predominantly in the heart, and causing airway constriction via ?2 receptors, located predominantly in the bronchial muscle of the airways. The drug is currently marketed under various brands including Corgard and Novo-Nadolol. The company evaluated nadolol in a phase II clinical trial, and results show that it is safe and effective in smoking cessation.
Products detail in the report…
Cytisinicline (cytisine): Achieve Life Sciences
Cytisinicline (also known as cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe (as Tabex) for more than 20 years. Cytisinicline’s dual-acting MOA specifically targets the ?4?2 nicotine receptor. Through its partial agonist/partial antagonist activity, it is believed to help reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking. The company is launching a phase III clinical trial in Q4 with designs and NDA plans already reviewed with the FDA. It was also studied in phase III clinical trial comparing cytosine and varenicline. Achieve Life Sciences also completed the development of phase II ORCA-V1 trial protocol to evaluate cytisinicline in this rapidly growing population of e-cigarette users. Currently, the company is pursuing non-dilutive funding sources to help support this initiative.
Products detail in the report…
List to be continued in the report…
Smoking Cessation Market Outlook
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. There are 89 distinct products and services available today for smoking cessation, alongside 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy (NRT) in the form of a transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline. Nortriptyline and clonidine have been shown in clinical trials to promote smoking cessation, but regulatory authorities have not approved them for this purpose.
In the EU, varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Cytisine is a generic agent currently manufactured by Sopharma as Tabex and by Aflofarm Pharma as Desmoxan. It has been available both with and without prescription for smoking cessation since the 1960s, largely in Eastern Europe. The basic patent of Chantix/Champix is about to expire in 2021 in the EU and in 2022 in Japan. In Japan, varenicline (Champix), NRT, and some off-label therapies are used for smoking cessation. Bupropion-SR is not licensed in Japan for smoking cessation.
For smokeless tobacco users, counseling and support in changing behavior appear to be effective, while the evidence for nicotine replacement and other drugs is weak. Nonpharmacologic therapy, such as individual or group counseling, is necessary to address the important role of conditioning in tobacco addiction, which is not completely addressed using pharmacologic means. Briefly, ideal characteristics of effective nonpharmacologic treatment include those that improve skills necessary to achieve and maintain abstinence, such as those that teach coping mechanisms for craving and aversive abstinence symptoms.
According to DelveInsight, Smoking Cessation 7MM is expected to change in the study period 2017–2030.
Key Findings
This section provides the total Smoking Cessation market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Smoking Cessation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Smoking Cessation market size and market size by therapies in Japan are provided.
Smoking Cessation Drugs Uptake
This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017–2030. The analysis covers Smoking Cessation market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Smoking Cessation Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Smoking Cessation emerging therapies.
Reimbursement Scenario in Smoking Cessation
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Smoking Cessation market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
Market Insights:
DelveInsight’s ‘Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Smoking Cessation market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Smoking Cessation market size from 2017 to 2030. The Report also covers current Smoking Cessation treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Smoking Cessation Understanding and Treatment Algorithm
Smoking Cessation Overview
Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.
The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.
Smoking Cessation Symptoms
Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like “riding a roller coaster”—there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2–4 weeks after stopping.
Continued in the report
Smoking Cessation Treatment
The treatment of smoking includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.
Varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Nortriptyline and clonidine are also used in smoking cessation as off-label medicines.
In the United States, NRT is available over the counter or by prescription as patches, gum, and lozenges, and by prescription only as a nasal spray and oral inhaler. NRT provides nicotine to reduce withdrawal symptoms, including irritability, anxiety, difficulty concentrating, dysphoria, hunger, weight gain, and sleep disturbances, which occur when a smoker stops smoking.
Non-pharmacological treatments for tobacco dependence include behavioral skills training using cognitive behavioral therapy techniques, motivational interviewing, and incentives to motivate and reinforce behavior change.
Smoking Cessation Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Key Findings
- The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017.
- The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU5, and Japan. In 2017, the number of smokers in the US was estimated to be 35,288,932.
- In the US, there were 19,303,046 diagnosed prevalent cases of smokers among males and 15,985,886 diagnosed prevalent cases among females in 2017.
- Out of the total 35,288,932 diagnosed prevalent cases of smokers in the US, the highest cases were observed in the age group 45–64 years (14,080,284) and the least cases were observed in 18-24 years (3,140,715) in the year 2017.
- Among the European-5 countries, Germany had the highest diagnosed prevalent population of smokers with 19,305,099 cases, followed by France with 14,044,812 cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of 7,750,777 in 2017.
- Japan had 19,411,835 diagnosed prevalent cases of smokers in 2017, and out of this approximately 5,610,020 diagnosed cases of smoking cessation were estimated.
The epidemiology segment also provides the Smoking Cessation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Smoking Cessation Drug Chapters
The drug chapter segment of the Smoking Cessation report encloses the detailed analysis of Smoking Cessation current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the Smoking Cessation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.
Smoking Cessation Marketed Drugs
Varenicline (Chantix/Champix): Pfizer
Varenicline is a medication used for smoking cessation aids. It works by blocking the pleasant effects of nicotine (from smoking) on the brain. It is used together with behavior modification and counseling support to help stop smoking. In May 2006, the US FDA approved varenicline (Chantix, Champix) for use in smoking cessation; it was the first oral non?nicotine treatment licensed by the FDA. It was also approved in the EU and Japan for smoking cessation. Patients should be treated with Chantix for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks of treatment with Chantix is recommended to increase the likelihood of long-term abstinence further.
Varenicline binds with high affinity and selectivity at ?4?2 neuronal nicotinic acetylcholine receptors. The efficacy of Chantix in smoking cessation is believed to be the result of varenicline’s activity at the ?4?2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.
Products detail in the report…
Bupropion (Zyban): GlaxoSmithKline
Bupropion is a selective inhibitor of the neuronal reuptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin). It is indicated as an aid to smoking cessation treatment. The exact mechanism by which Zyban enhances the ability of patients to abstain from smoking is not known but is presumed to be related to noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase. The FDA approved it in 1997. It is also approved in the EU for the treatment of smoking cessation.
Products detail in the report…
Smoking Cessation Emerging Drugs
AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, in clinical development for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and smoking cessation. The drug consists of dextromethorphan (DM) and bupropion and utilizes Axsome’s metabolic inhibition technology. The DM component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and an inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor. Both components are nicotinic acetylcholine receptor antagonists and have demonstrated anti-inflammatory properties. The company plans to meet with the FDA in the second half of 2020 to discuss the continued clinical development of AXS-05 as an aid to smoking cessation treatment.
Products detail in the report…
Nadolol (INV102): Chronic Airway Therapeutics
Nadolol (INV102) is a beta-adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium to treat chronic respiratory diseases. Used acutely, Nadolol blocks both ?1 and ?2 receptors, causing a decrease in heart rate and blood pressure via ?1 receptors, which are located predominantly in the heart, and causing airway constriction via ?2 receptors, located predominantly in the bronchial muscle of the airways. The drug is currently marketed under various brands including Corgard and Novo-Nadolol. The company evaluated nadolol in a phase II clinical trial, and results show that it is safe and effective in smoking cessation.
Products detail in the report…
Cytisinicline (cytisine): Achieve Life Sciences
Cytisinicline (also known as cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe (as Tabex) for more than 20 years. Cytisinicline’s dual-acting MOA specifically targets the ?4?2 nicotine receptor. Through its partial agonist/partial antagonist activity, it is believed to help reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking. The company is launching a phase III clinical trial in Q4 with designs and NDA plans already reviewed with the FDA. It was also studied in phase III clinical trial comparing cytosine and varenicline. Achieve Life Sciences also completed the development of phase II ORCA-V1 trial protocol to evaluate cytisinicline in this rapidly growing population of e-cigarette users. Currently, the company is pursuing non-dilutive funding sources to help support this initiative.
Products detail in the report…
List to be continued in the report…
Smoking Cessation Market Outlook
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. There are 89 distinct products and services available today for smoking cessation, alongside 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy (NRT) in the form of a transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline. Nortriptyline and clonidine have been shown in clinical trials to promote smoking cessation, but regulatory authorities have not approved them for this purpose.
In the EU, varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Cytisine is a generic agent currently manufactured by Sopharma as Tabex and by Aflofarm Pharma as Desmoxan. It has been available both with and without prescription for smoking cessation since the 1960s, largely in Eastern Europe. The basic patent of Chantix/Champix is about to expire in 2021 in the EU and in 2022 in Japan. In Japan, varenicline (Champix), NRT, and some off-label therapies are used for smoking cessation. Bupropion-SR is not licensed in Japan for smoking cessation.
For smokeless tobacco users, counseling and support in changing behavior appear to be effective, while the evidence for nicotine replacement and other drugs is weak. Nonpharmacologic therapy, such as individual or group counseling, is necessary to address the important role of conditioning in tobacco addiction, which is not completely addressed using pharmacologic means. Briefly, ideal characteristics of effective nonpharmacologic treatment include those that improve skills necessary to achieve and maintain abstinence, such as those that teach coping mechanisms for craving and aversive abstinence symptoms.
According to DelveInsight, Smoking Cessation 7MM is expected to change in the study period 2017–2030.
Key Findings
- The market size of Smoking Cessation in the 7MM was USD 2,874.8 million in 2017.
- According to the estimates, the highest market size of smoking cessation is found in the United States, followed by Japan and France.
- The current market for Smoking Cessation includes three major therapies Varenicline (Chantix), Bupropion-SR (Zyban), and nicotine replacement therapies (NRT). NRT includes inhaler, nasal spray, patch, gum, and lozenge.
- The emerging therapies for Smoking Cessation include AXS-05, Cytisinicline, and NFL-101, which are expected to enter the market during the forecasted period (2020–2030).
- Among the EU-5 countries, France has the highest market size of USD 151.3 million, followed by Spain and the United Kingdom in 2017. The lowest market size was estimated in Germany with USD 77.8 million in 2017.
- The total market size of Smoking Cessation in Japan was estimated to be USD 333.5 million in 2017.
This section provides the total Smoking Cessation market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Smoking Cessation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Smoking Cessation market size and market size by therapies in Japan are provided.
Smoking Cessation Drugs Uptake
This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017–2030. The analysis covers Smoking Cessation market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Smoking Cessation Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Smoking Cessation emerging therapies.
Reimbursement Scenario in Smoking Cessation
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Smoking Cessation market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Smoking Cessation, explaining symptoms of nicotine withdrawal and currently available therapies.
- Comprehensive insight has been provided into the Smoking Cessation epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Smoking Cessation is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Smoking Cessation market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Smoking Cessation market.
- The increasing diagnosed prevalence of the Smoking Cessation along with promising emerging pipeline therapies will positively drive the Smoking Cessation market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation R&D.
- Major players are involved in developing therapies for Smoking Cessation. The launch of emerging therapies will significantly impact the Smoking Cessation market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
- Patient Population
- Therapeutic Approaches
- Smoking Cessation Pipeline Analysis
- Smoking Cessation Market Size and Trends
- Market Opportunities
- Impact of Upcoming Therapies
- Eleven Years Forecast
- 7MM Coverage
- Smoking Cessation Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT Analysis
- Market Access and Reimbursement
Market Insights:
- What was the Smoking Cessation market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Smoking Cessation total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest Smoking Cessation market size during the forecast period (2020–2030)?
- At what CAGR, the Smoking Cessation market is expected to grow at the 7MM level during the forecast period (2020–2030)?
- What would be the Smoking Cessation market outlook across the 7MM during the forecast period (2020–2030)?
- What would be the Smoking Cessation market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What are the disease risk, burden, and unmet needs of Smoking Cessation?
- What is the historical Smoking Cessation patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Smoking Cessation at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Smoking Cessation?
- Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Smoking Cessation during the forecast period (2020–2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
- What are the current options for the treatment of Smoking Cessation along with the approved therapy?
- What are the Smoking Cessation emerging drugs and their MOA, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for Smoking Cessation?
- How many emerging therapies are in the mid-stage and late stages of development for Smoking Cessation?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Smoking Cessation and their status?
- What are the key designations that have been granted for the emerging therapies for Smoking Cessation?
- What are the 7MM historical and forecasted market of Smoking Cessation?
- The report will help in developing business strategies by understanding trends shaping and driving the Smoking Cessation.
- To understand the future market competition in the Smoking Cessation market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Smoking Cessation in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Smoking Cessation market.
- To understand the future market competition in the Smoking Cessation market.
1. KEY INSIGHTS
2. EXECUTIVE SUMMARY OF SMOKING CESSATION
3. SMOKING CESSATION MARKET OVERVIEW AT A GLANCE
3.1. Total Market Share (%) Distribution of Smoking Cessation in 2017
3.2. Total Market Share (%) Distribution of Smoking Cessation in 2030
4. DISEASE BACKGROUND AND OVERVIEW: SMOKING CESSATION
4.1. Introduction
4.2. Symptoms of Nicotine Withdrawal
4.3. Barriers to Smoking Cessation
4.3.1. Addiction
4.3.2. Fear of weight gain
4.3.3. Depression
5. CASE REPORTS
5.1. Combination of Varenicline and Nicotine patch for Smoking Cessation: A case report
5.2. Smoking Cessation in a Woman with Breast Cancer, Cardiovascular Problems, and Depressive Symptomatology: Case Study
5.3. Abrupt Increase in Glucose Intolerance after Smoking Cessation Therapy: A Case Report
6. PATIENT JOURNEY
7. EPIDEMIOLOGY AND PATIENT POPULATION
7.1. Key Findings
7.2. KOL Views
7.3. Epidemiology Methodology
7.4. Total Diagnosed Prevalent Cases of Smokers in the 7MM
7.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM
8. UNITED STATES EPIDEMIOLOGY
8.1. Assumptions and Rationale
8.2. Total Diagnosed Prevalent Cases of Smokers in the United States
8.3. Gender-specific Diagnosed Prevalent Cases of Smokers in the United States
8.4. Age-specific Diagnosed Prevalent Cases of Smokers in the United States
8.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the United States
9. EU5 EPIDEMIOLOGY
9.1. Germany Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Diagnosed Prevalent Cases of Smokers in Germany
9.1.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Germany
9.1.4. Age-specific Diagnosed Prevalent Cases of Smokers in Germany
9.1.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Germany
9.2. France Epidemiology
9.2.1. Assumptions and rationale
9.2.2. Total Diagnosed Prevalent Cases of Smokers in France
9.2.3. Gender-specific Diagnosed Prevalent Cases of Smokers in France
9.2.4. Age-specific Diagnosed Prevalent Cases of Smokers in France
9.2.5. Total Diagnosed Prevalent Cases of Smoking Cessation in France
9.3. Italy Epidemiology
9.3.1. Assumptions and Rationale
9.3.2. Total Diagnosed Prevalent Cases of Smokers in Italy
9.3.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Italy
9.3.4. Age-specific Diagnosed Prevalent Cases of Smokers in Italy
9.3.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Italy
9.4. Spain Epidemiology
9.4.1. Assumptions and Rationale
9.4.2. Total Diagnosed Prevalent Cases of Smokers in Spain
9.4.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Spain
9.4.4. Age-specific Diagnosed Prevalent Cases of Smokers in Spain
9.4.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Spain
9.5. United Kingdom Epidemiology
9.5.1. Assumptions and Rationale
9.5.2. Total Diagnosed Prevalent Cases of Smokers in the United Kingdom
9.5.3. Gender-specific Diagnosed Prevalent Cases of Smokers in the United Kingdom
9.5.4. Age-specific Diagnosed Prevalent Cases of Smokers in the United Kingdom
9.5.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the UK
10. JAPAN EPIDEMIOLOGY
10.1. Assumptions and Rationale
10.2. Total Diagnosed Prevalent Cases of Smokers in Japan
10.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Japan
10.4 .Age-specific Diagnosed Prevalent Cases of Smokers in Japan
10.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Japan
11. CURRENT TREATMENT AND MEDICAL PRACTICES
11.1.Treatment
11.1.1. Treatment Options: Pharmacological Interventions
11.1.2. Treatment Options: Non-pharmacological Behavioral Interventions
11.2. Smoking Cessation Consulting Strategy
11.3. Decision Pathway for Smoking Cessation Treatment
11.3.1. Algorithm for Current Smokers
11.3.2. Treatment Algorithm for Former Smokers
11.3.3. Treatment Algorithm for Patients Not Ready to Make a Quit Attempt
11.4.Treatment Guidelines
11.4.1. US Public Health Service Guideline for Treating Tobacco Use and Dependence: 2008 Update
11.4.2. US Preventive Services Task Force Recommendation
12. UNMET NEEDS
13. MARKETED DRUGS
13.1. Varenicline (Chantix/Champix): Pfizer
13.1.1. Drug Description
13.1.2. Regulatory Milestones
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.1.5. Product Profile
13.2. Bupropion (Zyban): GlaxoSmithKline
13.2.1. Product Description
13.2.2. Regulatory Milestones
13.2.3. Other Developmental Activities
13.2.4. Clinical Development
13.2.5. Safety and Efficacy
13.2.6. Product Profile
14. EMERGING THERAPIES
14.1. Key Cross Competition
14.2. AXS-05: Axsome Therapeutics
14.2.1. Product Description
14.2.2. Other Developmental Activities
14.2.3. Clinical Development
14.2.4. Safety and Efficacy
14.2.5. Product Profile
14.3. Cytisinicline (Cytisine): Achieve Life Sciences
14.3.1. Product Description
14.3.2. Other Developmental Activities
14.3.3. Clinical Development
14.3.4. Safety and Efficacy
14.3.5. Product Profile
14.4. Nadolol (INV102): Chronic Airway Therapeutics
14.4.1. Product Description
14.4.2. Other Developmental Activities
14.4.3. Clinical Development
14.4.4. Safety and Efficacy
14.4.5. Product Profile
14.5. NFL-101: Smoke Free Therapeutics (NFL Biosciences SAS)
14.5.1. Product Description
14.5.2. Other Developmental Activities
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
14.5.5. Product Profile
14.6. Liraglutide: Novo Nordisk
14.6.1. Product Description
14.6.2. Clinical Development
14.6.3. Product Profile
15. SMOKING CESSATION: 7MM MARKET ANALYSIS
15.1. Key Findings
15.2. Market Methodology
15.3. Attribute Analysis
15.4. Key Market Forecast Assumptions
15.5. Market Size of Smoking Cessation in the 7MM
15.6. Market Size of Smoking Cessation by Therapies in the 7MM
15.7. Smoking Cessation Market Outlook of the 7MM
16. POTENTIAL OF EMERGING THERAPIES
17. UNITED STATES MARKET SIZE
17.1. Total Market Size of Smoking Cessation
17.2. Market Size of Smoking Cessation by Therapies in the US
18. EU-5 COUNTRIES: MARKET SIZE
18.1. Germany Market Size
18.1.1. Total Market Size of Smoking Cessation
18.1.2. Market Size of Smoking Cessation by Therapies in Germany
18.2. France Market Size
18.2.1. Total Market size of Smoking Cessation
18.2.2. Market Size of Smoking Cessation by Therapies in France
18.3. Italy Market Size
18.3.1. Total Market size of Smoking Cessation
18.3.2. Market Size of Smoking Cessation by Therapies in Italy
18.4. Spain Market Size
18.4.1. Total Market size of Smoking Cessation
18.4.2. Market Size of Smoking Cessation by Therapies in Spain
18.5. United Kingdom Market Size
18.5.1. Total Market size of Smoking Cessation
18.5.2. Market Size of Smoking Cessation by Therapies in the UK
19. JAPAN MARKET SIZE
19.1. Total Market size of Smoking Cessation
19.2. Market Size of Smoking Cessation by Therapies in Japan
20. MARKET DRIVERS
21. MARKET BARRIERS
22. SWOT ANALYSIS
23. REIMBURSEMENT AND MARKET ACCESS
24. RECOGNIZED ESTABLISHMENTS
25. APPENDIX
25.1.Bibliography
25.2.Report Methodology
26. DELVEINSIGHT CAPABILITIES
27. DISCLAIMER
28. ABOUT DELVEINSIGHT
2. EXECUTIVE SUMMARY OF SMOKING CESSATION
3. SMOKING CESSATION MARKET OVERVIEW AT A GLANCE
3.1. Total Market Share (%) Distribution of Smoking Cessation in 2017
3.2. Total Market Share (%) Distribution of Smoking Cessation in 2030
4. DISEASE BACKGROUND AND OVERVIEW: SMOKING CESSATION
4.1. Introduction
4.2. Symptoms of Nicotine Withdrawal
4.3. Barriers to Smoking Cessation
4.3.1. Addiction
4.3.2. Fear of weight gain
4.3.3. Depression
5. CASE REPORTS
5.1. Combination of Varenicline and Nicotine patch for Smoking Cessation: A case report
5.2. Smoking Cessation in a Woman with Breast Cancer, Cardiovascular Problems, and Depressive Symptomatology: Case Study
5.3. Abrupt Increase in Glucose Intolerance after Smoking Cessation Therapy: A Case Report
6. PATIENT JOURNEY
7. EPIDEMIOLOGY AND PATIENT POPULATION
7.1. Key Findings
7.2. KOL Views
7.3. Epidemiology Methodology
7.4. Total Diagnosed Prevalent Cases of Smokers in the 7MM
7.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM
8. UNITED STATES EPIDEMIOLOGY
8.1. Assumptions and Rationale
8.2. Total Diagnosed Prevalent Cases of Smokers in the United States
8.3. Gender-specific Diagnosed Prevalent Cases of Smokers in the United States
8.4. Age-specific Diagnosed Prevalent Cases of Smokers in the United States
8.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the United States
9. EU5 EPIDEMIOLOGY
9.1. Germany Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Diagnosed Prevalent Cases of Smokers in Germany
9.1.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Germany
9.1.4. Age-specific Diagnosed Prevalent Cases of Smokers in Germany
9.1.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Germany
9.2. France Epidemiology
9.2.1. Assumptions and rationale
9.2.2. Total Diagnosed Prevalent Cases of Smokers in France
9.2.3. Gender-specific Diagnosed Prevalent Cases of Smokers in France
9.2.4. Age-specific Diagnosed Prevalent Cases of Smokers in France
9.2.5. Total Diagnosed Prevalent Cases of Smoking Cessation in France
9.3. Italy Epidemiology
9.3.1. Assumptions and Rationale
9.3.2. Total Diagnosed Prevalent Cases of Smokers in Italy
9.3.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Italy
9.3.4. Age-specific Diagnosed Prevalent Cases of Smokers in Italy
9.3.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Italy
9.4. Spain Epidemiology
9.4.1. Assumptions and Rationale
9.4.2. Total Diagnosed Prevalent Cases of Smokers in Spain
9.4.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Spain
9.4.4. Age-specific Diagnosed Prevalent Cases of Smokers in Spain
9.4.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Spain
9.5. United Kingdom Epidemiology
9.5.1. Assumptions and Rationale
9.5.2. Total Diagnosed Prevalent Cases of Smokers in the United Kingdom
9.5.3. Gender-specific Diagnosed Prevalent Cases of Smokers in the United Kingdom
9.5.4. Age-specific Diagnosed Prevalent Cases of Smokers in the United Kingdom
9.5.5. Total Diagnosed Prevalent Cases of Smoking Cessation in the UK
10. JAPAN EPIDEMIOLOGY
10.1. Assumptions and Rationale
10.2. Total Diagnosed Prevalent Cases of Smokers in Japan
10.3. Gender-specific Diagnosed Prevalent Cases of Smokers in Japan
10.4 .Age-specific Diagnosed Prevalent Cases of Smokers in Japan
10.5. Total Diagnosed Prevalent Cases of Smoking Cessation in Japan
11. CURRENT TREATMENT AND MEDICAL PRACTICES
11.1.Treatment
11.1.1. Treatment Options: Pharmacological Interventions
11.1.2. Treatment Options: Non-pharmacological Behavioral Interventions
11.2. Smoking Cessation Consulting Strategy
11.3. Decision Pathway for Smoking Cessation Treatment
11.3.1. Algorithm for Current Smokers
11.3.2. Treatment Algorithm for Former Smokers
11.3.3. Treatment Algorithm for Patients Not Ready to Make a Quit Attempt
11.4.Treatment Guidelines
11.4.1. US Public Health Service Guideline for Treating Tobacco Use and Dependence: 2008 Update
11.4.2. US Preventive Services Task Force Recommendation
12. UNMET NEEDS
13. MARKETED DRUGS
13.1. Varenicline (Chantix/Champix): Pfizer
13.1.1. Drug Description
13.1.2. Regulatory Milestones
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.1.5. Product Profile
13.2. Bupropion (Zyban): GlaxoSmithKline
13.2.1. Product Description
13.2.2. Regulatory Milestones
13.2.3. Other Developmental Activities
13.2.4. Clinical Development
13.2.5. Safety and Efficacy
13.2.6. Product Profile
14. EMERGING THERAPIES
14.1. Key Cross Competition
14.2. AXS-05: Axsome Therapeutics
14.2.1. Product Description
14.2.2. Other Developmental Activities
14.2.3. Clinical Development
14.2.4. Safety and Efficacy
14.2.5. Product Profile
14.3. Cytisinicline (Cytisine): Achieve Life Sciences
14.3.1. Product Description
14.3.2. Other Developmental Activities
14.3.3. Clinical Development
14.3.4. Safety and Efficacy
14.3.5. Product Profile
14.4. Nadolol (INV102): Chronic Airway Therapeutics
14.4.1. Product Description
14.4.2. Other Developmental Activities
14.4.3. Clinical Development
14.4.4. Safety and Efficacy
14.4.5. Product Profile
14.5. NFL-101: Smoke Free Therapeutics (NFL Biosciences SAS)
14.5.1. Product Description
14.5.2. Other Developmental Activities
14.5.3. Clinical Development
14.5.4. Safety and Efficacy
14.5.5. Product Profile
14.6. Liraglutide: Novo Nordisk
14.6.1. Product Description
14.6.2. Clinical Development
14.6.3. Product Profile
15. SMOKING CESSATION: 7MM MARKET ANALYSIS
15.1. Key Findings
15.2. Market Methodology
15.3. Attribute Analysis
15.4. Key Market Forecast Assumptions
15.5. Market Size of Smoking Cessation in the 7MM
15.6. Market Size of Smoking Cessation by Therapies in the 7MM
15.7. Smoking Cessation Market Outlook of the 7MM
16. POTENTIAL OF EMERGING THERAPIES
17. UNITED STATES MARKET SIZE
17.1. Total Market Size of Smoking Cessation
17.2. Market Size of Smoking Cessation by Therapies in the US
18. EU-5 COUNTRIES: MARKET SIZE
18.1. Germany Market Size
18.1.1. Total Market Size of Smoking Cessation
18.1.2. Market Size of Smoking Cessation by Therapies in Germany
18.2. France Market Size
18.2.1. Total Market size of Smoking Cessation
18.2.2. Market Size of Smoking Cessation by Therapies in France
18.3. Italy Market Size
18.3.1. Total Market size of Smoking Cessation
18.3.2. Market Size of Smoking Cessation by Therapies in Italy
18.4. Spain Market Size
18.4.1. Total Market size of Smoking Cessation
18.4.2. Market Size of Smoking Cessation by Therapies in Spain
18.5. United Kingdom Market Size
18.5.1. Total Market size of Smoking Cessation
18.5.2. Market Size of Smoking Cessation by Therapies in the UK
19. JAPAN MARKET SIZE
19.1. Total Market size of Smoking Cessation
19.2. Market Size of Smoking Cessation by Therapies in Japan
20. MARKET DRIVERS
21. MARKET BARRIERS
22. SWOT ANALYSIS
23. REIMBURSEMENT AND MARKET ACCESS
24. RECOGNIZED ESTABLISHMENTS
25. APPENDIX
25.1.Bibliography
25.2.Report Methodology
26. DELVEINSIGHT CAPABILITIES
27. DISCLAIMER
28. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1 Summary of Smoking Cessation, Market, Epidemiology, and Key Events (2017–2030)
Table 2 Total Diagnosed Prevalent Cases of Smokers in the 7MM (2017–2030)
Table 3 Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM (2017–2030)
Table 4 Total Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Table 5 Gender-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Table 6 Age-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Table 7 Total Diagnosed Prevalent Cases of Smoking Cessation in the US (2017–2030)
Table 8 Total Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Table 9 Gender-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Table 10 Age-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Table 11 Total Diagnosed Prevalent Cases of Smoking Cessation in Germany (2017–2030)
Table 12 Total Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Table 13 Gender-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Table 14 Age-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Table 15 Total Diagnosed Prevalent Cases of Smoking Cessation in France (2017–2030)
Table 16 Total Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Table 17 Gender-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Table 18 Age-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Table 19 Total Diagnosed Prevalent Cases of Smoking Cessation in Italy (2017–2030)
Table 20 Total Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Table 21 Gender-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Table 22 Age-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Table 23 Total Diagnosed Prevalent Cases of Smoking Cessation in Spain (2017–2030)
Table 24 Total Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Table 25 Gender-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Table 26 Age-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Table 27 Total Diagnosed Prevalent Cases of Smoking Cessation in the UK (2017–2030)
Table 28 Total Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Table 29 Gender-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Table 30 Age-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Table 31 Total Diagnosed Prevalent Cases of Smoking Cessation in Japan (2017–2030)
Table 32 Current pharmacotherapies for smoking cessation
Table 33 Stages of Behavior Change
Table 34 Five R's Strategy for Motivating Patients to Quit Smoking
Table 35 Behavioral and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women
Table 36 Varenicline, Clinical Trial Description, 2020
Table 37 Bupropion, Clinical Trial Description, 2020
Table 38 Comparison of emerging drugs under development
Table 39 AXS-05, Clinical Trial Description, 2020
Table 40 Cytisinicline, Clinical Trial Description, 2020
Table 41 Nadolol, Clinical Trial Description, 2020
Table 42 NFL-101, Clinical Trial Description, 2020
Table 43 Liraglutide, Clinical Trial Description, 2020
Table 44 Key Market Forecast Assumptions for Cytisinicline
Table 45 Key Market Forecast Assumptions for AXS-05
Table 46 Key Market Forecast Assumptions for NFL-101
Table 47 Market Size of Smoking Cessation in the 7MM in USD Million (2017–2030)
Table 48 Market Size of Smoking Cessation by Therapies in the 7MM, in USD Million (2017–2030)
Table 49 The US Market Size of Smoking Cessation in USD Million (2017–2030)
Table 50 Market Size of Smoking Cessation by Therapies in the US, in USD Million (2017–2030)
Table 51 Germany Market Size of Smoking Cessation in USD Million (2017–2030)
Table 52 Market Size of Smoking Cessation by Therapies in Germany, in USD Million (2017–2030)
Table 53 France Market Size of Smoking Cessation in USD Million (2017–2030)
Table 54 Market Size of Smoking Cessation by Therapies in France, in USD Million (2017–2030)
Table 55 Italy Market Size of Smoking Cessation in USD Million (2017–2030)
Table 56 Market Size of Smoking Cessation by Therapies in Italy, in USD Million (2017–2030)
Table 57 Spain Market Size of Smoking Cessation in USD Million (2017–2030)
Table 58 Market Size of Smoking Cessation by Therapies in Spain, in USD Million (2017–2030)
Table 59 UK Market Size of Smoking Cessation in USD Million (2017–2030)
Table 60 Market Size of Smoking Cessation by Therapies in the UK, in USD Million (2017–2030)
Table 61 Japan Market Size of Smoking Cessation in USD Million (2017–2030)
Table 62 Market Size of Smoking Cessation by Therapies in Japan, in USD Million (2017–2030)
Table 63 Models of comprehensive tobacco cessation coverage and health insurance benefits
Table 1 Summary of Smoking Cessation, Market, Epidemiology, and Key Events (2017–2030)
Table 2 Total Diagnosed Prevalent Cases of Smokers in the 7MM (2017–2030)
Table 3 Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM (2017–2030)
Table 4 Total Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Table 5 Gender-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Table 6 Age-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Table 7 Total Diagnosed Prevalent Cases of Smoking Cessation in the US (2017–2030)
Table 8 Total Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Table 9 Gender-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Table 10 Age-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Table 11 Total Diagnosed Prevalent Cases of Smoking Cessation in Germany (2017–2030)
Table 12 Total Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Table 13 Gender-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Table 14 Age-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Table 15 Total Diagnosed Prevalent Cases of Smoking Cessation in France (2017–2030)
Table 16 Total Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Table 17 Gender-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Table 18 Age-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Table 19 Total Diagnosed Prevalent Cases of Smoking Cessation in Italy (2017–2030)
Table 20 Total Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Table 21 Gender-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Table 22 Age-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Table 23 Total Diagnosed Prevalent Cases of Smoking Cessation in Spain (2017–2030)
Table 24 Total Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Table 25 Gender-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Table 26 Age-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Table 27 Total Diagnosed Prevalent Cases of Smoking Cessation in the UK (2017–2030)
Table 28 Total Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Table 29 Gender-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Table 30 Age-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Table 31 Total Diagnosed Prevalent Cases of Smoking Cessation in Japan (2017–2030)
Table 32 Current pharmacotherapies for smoking cessation
Table 33 Stages of Behavior Change
Table 34 Five R's Strategy for Motivating Patients to Quit Smoking
Table 35 Behavioral and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women
Table 36 Varenicline, Clinical Trial Description, 2020
Table 37 Bupropion, Clinical Trial Description, 2020
Table 38 Comparison of emerging drugs under development
Table 39 AXS-05, Clinical Trial Description, 2020
Table 40 Cytisinicline, Clinical Trial Description, 2020
Table 41 Nadolol, Clinical Trial Description, 2020
Table 42 NFL-101, Clinical Trial Description, 2020
Table 43 Liraglutide, Clinical Trial Description, 2020
Table 44 Key Market Forecast Assumptions for Cytisinicline
Table 45 Key Market Forecast Assumptions for AXS-05
Table 46 Key Market Forecast Assumptions for NFL-101
Table 47 Market Size of Smoking Cessation in the 7MM in USD Million (2017–2030)
Table 48 Market Size of Smoking Cessation by Therapies in the 7MM, in USD Million (2017–2030)
Table 49 The US Market Size of Smoking Cessation in USD Million (2017–2030)
Table 50 Market Size of Smoking Cessation by Therapies in the US, in USD Million (2017–2030)
Table 51 Germany Market Size of Smoking Cessation in USD Million (2017–2030)
Table 52 Market Size of Smoking Cessation by Therapies in Germany, in USD Million (2017–2030)
Table 53 France Market Size of Smoking Cessation in USD Million (2017–2030)
Table 54 Market Size of Smoking Cessation by Therapies in France, in USD Million (2017–2030)
Table 55 Italy Market Size of Smoking Cessation in USD Million (2017–2030)
Table 56 Market Size of Smoking Cessation by Therapies in Italy, in USD Million (2017–2030)
Table 57 Spain Market Size of Smoking Cessation in USD Million (2017–2030)
Table 58 Market Size of Smoking Cessation by Therapies in Spain, in USD Million (2017–2030)
Table 59 UK Market Size of Smoking Cessation in USD Million (2017–2030)
Table 60 Market Size of Smoking Cessation by Therapies in the UK, in USD Million (2017–2030)
Table 61 Japan Market Size of Smoking Cessation in USD Million (2017–2030)
Table 62 Market Size of Smoking Cessation by Therapies in Japan, in USD Million (2017–2030)
Table 63 Models of comprehensive tobacco cessation coverage and health insurance benefits
LIST OF FIGURES
Figure 1 Stages of the addiction cycle
Figure 2 Tobacco and Cancer
Figure 3 Patient Journey
Figure 4 KOL Views
Figure 5 Total Diagnosed Prevalent Cases of Smokers in the 7MM (2017–2030)
Figure 6 Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM (2017–2030)
Figure 7 Total Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Figure 8 Gender-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Figure 9 Age-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Figure 10 Total Diagnosed Prevalent Cases of Smoking Cessation in the US (2017–2030)
Figure 11 Total Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Figure 12 Gender-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Figure 13 Age-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Figure 14 Total Diagnosed Prevalent Cases of Smoking Cessation in Germany (2017–2030)
Figure 15 Total Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Figure 18 Total Diagnosed Prevalent Cases of Smoking Cessation in France (2017–2030)
Figure 19 Total Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Figure 20 Gender-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Figure 21 Age-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Figure 22 Total Diagnosed Cases of Smoking Cessation in Italy (2017–2030)
Figure 23 Total Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Figure 24 Gender-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Figure 25 Age-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Figure 26 Total Diagnosed Prevalent Cases of Smoking Cessation in Spain (2017–2030)
Figure 27 Total Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Figure 28 Gender-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Figure 29 Age-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Figure 30 Total Diagnosed Prevalent Cases of Smoking Cessation in the UK (2017–2030)
Figure 31 Total Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Figure 32 Gender-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Figure 33 Age-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Figure 34 Total Diagnosed Prevalent Cases of Smoking Cessation in Japan (2017–2030)
Figure 35 Pathway for Tobacco Cessation Treatment
Figure 36 Algorithm for a Former Smoker
Figure 37 Algorithm for Patients Not Ready to Quit
Figure 38 Unmet needs
Figure 39 Total Market Size of Smoking Cessation in the 7MM in USD Million (2017–2030)
Figure 40 Market Size of Smoking Cessation by Therapies in the 7MM in USD Million (2017–2030)
Figure 41 Market Size of Smoking Cessation in the US, USD Millions (2017–2030)
Figure 42 Market Size of Smoking Cessation by Therapies in the US in USD Million (2017–2030)
Figure 43 Market Size of Smoking Cessation in Germany, USD Millions (2017–2030)
Figure 44 Market Size of Smoking Cessation by Therapies in Germany in USD Million (2017–2030)
Figure 45 Market Size of Smoking Cessation in France, USD Millions (2017–2030)
Figure 46 Market Size of Smoking Cessation by Therapies in France in USD Million (2017–2030)
Figure 47 Market Size of Smoking Cessation in Italy, USD Millions (2017–2030)
Figure 48 Market Size of Smoking Cessation by Therapies in Italy in USD Million (2017–2030)
Figure 49 Market Size of Smoking Cessation in Spain, USD Millions (2017–2030)
Figure 50 Market Size of Smoking Cessation by Therapies in Spain in USD Million (2017–2030)
Figure 51 Market Size of Smoking Cessation in the UK, USD Millions (2017–2030)
Figure 52 Market Size of Smoking Cessation by Therapies in the UK in USD Million (2017–2030)
Figure 53 Market Size of Smoking Cessation in Japan, USD Millions (2017–2030)
Figure 54 Market Size of Smoking Cessation by Therapies in Japan in USD Million (2017–2030)
Figure 55 Market Drivers
Figure 56 Market Barriers
Figure 57 SWOT analysis of smoking cessation
Figure 1 Stages of the addiction cycle
Figure 2 Tobacco and Cancer
Figure 3 Patient Journey
Figure 4 KOL Views
Figure 5 Total Diagnosed Prevalent Cases of Smokers in the 7MM (2017–2030)
Figure 6 Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM (2017–2030)
Figure 7 Total Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Figure 8 Gender-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Figure 9 Age-specific Diagnosed Prevalent Cases of Smokers in the US (2017–2030)
Figure 10 Total Diagnosed Prevalent Cases of Smoking Cessation in the US (2017–2030)
Figure 11 Total Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Figure 12 Gender-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Figure 13 Age-specific Diagnosed Prevalent Cases of Smokers in Germany (2017–2030)
Figure 14 Total Diagnosed Prevalent Cases of Smoking Cessation in Germany (2017–2030)
Figure 15 Total Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Figure 16 Gender-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Figure 17 Age-specific Diagnosed Prevalent Cases of Smokers in France (2017–2030)
Figure 18 Total Diagnosed Prevalent Cases of Smoking Cessation in France (2017–2030)
Figure 19 Total Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Figure 20 Gender-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Figure 21 Age-specific Diagnosed Prevalent Cases of Smokers in Italy (2017–2030)
Figure 22 Total Diagnosed Cases of Smoking Cessation in Italy (2017–2030)
Figure 23 Total Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Figure 24 Gender-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Figure 25 Age-specific Diagnosed Prevalent Cases of Smokers in Spain (2017–2030)
Figure 26 Total Diagnosed Prevalent Cases of Smoking Cessation in Spain (2017–2030)
Figure 27 Total Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Figure 28 Gender-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Figure 29 Age-specific Diagnosed Prevalent Cases of Smokers in the UK (2017–2030)
Figure 30 Total Diagnosed Prevalent Cases of Smoking Cessation in the UK (2017–2030)
Figure 31 Total Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Figure 32 Gender-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Figure 33 Age-specific Diagnosed Prevalent Cases of Smokers in Japan (2017–2030)
Figure 34 Total Diagnosed Prevalent Cases of Smoking Cessation in Japan (2017–2030)
Figure 35 Pathway for Tobacco Cessation Treatment
Figure 36 Algorithm for a Former Smoker
Figure 37 Algorithm for Patients Not Ready to Quit
Figure 38 Unmet needs
Figure 39 Total Market Size of Smoking Cessation in the 7MM in USD Million (2017–2030)
Figure 40 Market Size of Smoking Cessation by Therapies in the 7MM in USD Million (2017–2030)
Figure 41 Market Size of Smoking Cessation in the US, USD Millions (2017–2030)
Figure 42 Market Size of Smoking Cessation by Therapies in the US in USD Million (2017–2030)
Figure 43 Market Size of Smoking Cessation in Germany, USD Millions (2017–2030)
Figure 44 Market Size of Smoking Cessation by Therapies in Germany in USD Million (2017–2030)
Figure 45 Market Size of Smoking Cessation in France, USD Millions (2017–2030)
Figure 46 Market Size of Smoking Cessation by Therapies in France in USD Million (2017–2030)
Figure 47 Market Size of Smoking Cessation in Italy, USD Millions (2017–2030)
Figure 48 Market Size of Smoking Cessation by Therapies in Italy in USD Million (2017–2030)
Figure 49 Market Size of Smoking Cessation in Spain, USD Millions (2017–2030)
Figure 50 Market Size of Smoking Cessation by Therapies in Spain in USD Million (2017–2030)
Figure 51 Market Size of Smoking Cessation in the UK, USD Millions (2017–2030)
Figure 52 Market Size of Smoking Cessation by Therapies in the UK in USD Million (2017–2030)
Figure 53 Market Size of Smoking Cessation in Japan, USD Millions (2017–2030)
Figure 54 Market Size of Smoking Cessation by Therapies in Japan in USD Million (2017–2030)
Figure 55 Market Drivers
Figure 56 Market Barriers
Figure 57 SWOT analysis of smoking cessation
